Review
Oncology
Bruno Fattizzo, Fabio Serpenti, Wilma Barcellini, Chiara Caprioli
Summary: Hypoplastic myelodysplastic syndromes (hMDS) pose a diagnostic challenge, blending features of both MDS (dysplasia, genetic lesions, cytopenias) and aplastic anemia (low cellularity, autoimmunity). There are two potential hMDS phenotypes: one proinflammatory and autoimmune, resembling AA and responding to immunosuppression; the other MDS-like, dominated by genetic lesions and prone to leukemic evolution. Personalized treatment and monitoring based on the predominant hMDS phenotype may be beneficial for patient management.
Article
Medicine, General & Internal
Calogero Vetro, Valeria Di Giacomo, Donato Mannina, Silvana Magrin, Antonio Mule, Maria Enza Mitra, Sergio Siragusa, Andrea Duminuco, Bruno Garibaldi, Maria Cristina Emanuela Vadala, Francesco Di Raimondo, Giuseppe A. Palumbo
Summary: This prospective observational study confirms the efficacy of erythropoietin zeta in the treatment of low-risk myelodysplastic syndrome. The results demonstrate a significant improvement in hemoglobin levels with the use of erythropoietin zeta.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Jiahui Liu, Zhi Wang, Ying Yang, Yan Xiong, Wei Wang, Jianxing Qiu, Kai Zhao, Bo Zheng
Summary: Primary pericardial mesothelioma is an extremely rare tumor, and early identification and accurate diagnosis are crucial for improving clinical outcomes. This case report described a 70-year-old female patient presenting with dyspnea, and confirmed the diagnosis through a combination of multiple imaging modalities.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Review
Hematology
Maria Domenica Cappellini, Ali T. Taher, Amit Verma, Farrukh Shah, Olivier Hermine
Summary: Hematologic disorders like myelodysplastic syndromes and beta-thalassemia are characterized by ineffective erythropoiesis and anemia, usually managed through regular blood transfusions. However, treatments targeting the underlying mechanisms of ineffective erythropoiesis are limited, leading to a burden on patients, caregivers, and healthcare systems. This article provides an overview of the role of ineffective erythropoiesis in these disorders, discusses unmet needs in targeting it, and describes current management strategies and emerging treatments.
Article
Medical Laboratory Technology
Yulia O. Davydova, Elena N. Parovichnikova, Irina V. Galtseva, Alina V. Kokhno, Valentina N. Dvirnyk, Alla M. Kovrigina, Tatyana N. Obukhova, Nikolay M. Kapranov, Ksenia A. Nikiforova, Svetlana A. Glinkina, Vera V. Troitskaya, Elena A. Mikhailova, Zalina T. Fidarova, Tatyana N. Moiseeva, Elena A. Lukina, Nina V. Tsvetaeva, Olga F. Nikulina, Larisa A. Kuzmina, Valeriy G. Savchenko
Summary: The study aimed to determine the optimal MFC approach for MDS and found that iFC is a useful diagnostic tool in MDS, especially in low-grade MDS. The results support the utility of iFC in the diagnosis of MDS.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2021)
Review
Oncology
Namrata S. Chandhok, Mikkael A. Sekeres
Summary: MDS is a heterogeneous disorder characterized by ineffective hematopoiesis. Treatment goals should align with patient goals to achieve meaningful improvement in clinical care.
LEUKEMIA & LYMPHOMA
(2022)
Article
Integrative & Complementary Medicine
Teng Fan, Xiaomin Feng, Asumi Yokota, Weiyi Liu, Yuting Tang, Xiaomei Yan, Haiyan Xiao, Yue Wang, Zhongyang Deng, Pan Zhao, Mingjing Wang, Hongzhi Wang, Rou Ma, Xiaomei Hu, Gang Huang
Summary: Traditional Chinese Medicine (TCM) such as Arsenic dispensing powder (ADP) has shown superior efficacy in treating MDS patients by improving anemia and prolonging overall survival. ADP promotes erythropoiesis in both normal and MDS clones through the downregulation of HIF1A and upregulation of GATA factors, suggesting it as a promising drug for MDS treatment.
AMERICAN JOURNAL OF CHINESE MEDICINE
(2021)
Review
Oncology
Iris van der Strate, Fatemeh Kazemzadeh, Iris D. Nagtegaal, Debbie Robbrecht, Agnes van de Wouw, Catarina S. Padilla, Saskia Duijts, Manel Esteller, F. Anthony Greco, Nicholas Pavlidis, Amir Qaseem, Petur Snaebjornsson, Sophie Veldhuijzen van Zanten, Caroline Loef
Summary: The study proposes a multi-layer classification for the diagnostic workup of CUP using the Delphi method. The recommended initial diagnostic includes history and physical examination, full blood count, serum marker analysis, biopsy of accessible lesion, CT scan, and immunohistochemical testing. Consensus was also reached on the need for an ideal diagnostic lead time for CUP patients.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Medicine, General & Internal
Thea Sophie Kister, Maria Schmidt, Lara Heuft, Martin Federbusch, Michael Haase, Thorsten Kaiser
Summary: This study investigates the potential impact of sex and age on laboratory diagnostics and outcomes of acute kidney injury (AKI). The findings suggest that serum creatinine (SCr) as a diagnostic parameter for AKI has limitations, particularly in women and the elderly, leading to incorrect or delayed diagnosis. Sex and age should be considered in the diagnosis and staging of AKI.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Zhaolong Zeng, Xiangzheng Ma, Yifan Guo, Baodong Ye, Maosheng Xu, Wei Wang
Summary: IDEAL-IQ imaging can quantify fat fraction and iron content in bone marrow, aiding in distinguishing between patients with aplastic anemia and myelodysplastic syndrome.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2021)
Article
Medicine, General & Internal
Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Jake Shortt, David Valcarcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Ana Carolina Giuseppi, Sandra Kreitz, Veronika Pozharskaya, Karen L. Keeperman, Shelonitda Rose, Jeevan K. Shetty, Sheida Hayati, Sadanand Vodala, Thomas Prebet, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Pierre Fenaux, Guillermo Garcia-Manero
Summary: In this study, we report the results of a prespecified interim analysis of luspatercept versus epoetin alfa for the treatment of anaemia due to lower-risk myelodysplastic syndromes. The results showed that luspatercept improved the rate of red blood cell transfusion independence and increased hemoglobin levels compared to epoetin alfa.
Article
Hematology
Hanneke J. C. M. Wouters, Annette Conrads-Frank, Karin A. Koinig, Alex Smith, Ge Yu, Theo de Witte, Bruce H. R. Wolffenbuttel, Gerwin Huls, Uwe Siebert, Reinhard Stauder, Melanie M. van der Klauw
Summary: The study shows that lower-risk MDS patients have significantly lower HRQoL compared to the general population, and the negative impact is mainly caused by MDS itself rather than anemia, suggesting that treatment strategies should focus on improving underlying pathogenic mechanisms to enhance HRQoL.
ANNALS OF HEMATOLOGY
(2021)
Article
Oncology
Silvia Saumell, Miranda Fernandez-Serrano, Alba Mesa, Felix Lopez-Cadenas, Leonor Arenillas, Ana Alfonso, Maria Julia Montoro, Antonieta Molero, Pilar Leoz, Victoria Riego, Laura Gallur, Olga Salamero, Mayda Navarrete, Barbara Tazon-Vega, Margarita Ortega, Oscar Reig, Gael Roue, Xavier Calvo, Felipe Prosper, Maria Diez-Campelo, David Valcarcel
Summary: The presence of Micromegakaryocytes (microMKs) in MDS patients indicates poorer outcomes, including lower overall survival rate and higher risk of progression to AML. Additionally, incorporating microMKs into the IPSS-R score can improve accuracy, leading to reclassification of some patients into higher-risk groups.
LEUKEMIA & LYMPHOMA
(2022)
Article
Multidisciplinary Sciences
Chengyao Wan, Jing Wen, Xiaolin Liang, Qiongni Xie, Wenqi Wu, Meiqing Wu, Zhenfang Liu
Summary: The study found that the expression of the miR-320 family is up-regulated in MDS, serving as candidate diagnostic biomarkers for MDS. Additionally, high expression of miR-320d is an independent prognostic factor for overall survival in MDS.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Hana Votavova, Monika Belickova
Summary: The translated article discusses the differences between hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA), highlighting the importance of molecular testing.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2022)